アンジオテンシンは,脳内のセロトニンの放出と合成を調節する
Science (New York, N.Y.)
|December 8, 1978
まとめ
アンジオテンシンIIは,トリプトファンヒドロキシラーゼの活性化により,セロトニンの放出と合成を増加させ,セロトニンのレベルに影響を与えます. 効果は用量によって変化し,高用量では刺激を示し,低用量では阻害を示し,複雑なセロトニンシステムの調節を明らかにします.
科学分野:
- 神経科学は神経科学である.
- エンドクリノロジー エンドクリノロジー
- バイオケミストリー バイオケミストリー
背景:
- セロトニンは,様々な生理学的プロセスに関与する重要な神経伝達物質です.
- アンジオテンシンIIは,心血管系および神経系に知られた効果を持つホルモンです.
研究 の 目的:
- ニューロン末端におけるセロトニンの放出と合成に対するアンジオテンシンIIの効果を調査する.
- アンジオテンシンII媒介のセロトニン生成におけるトリプトファンヒドロキシラーゼの役割を明らかにする.
- セロトニン系におけるアニオテンシンIIの用量依存的効果を特徴づける.
主な方法:
- ニューロン端末からのセロトニン放出量の測定.
- トリプトファンヒドロキシラーゼの活性度の測定.
- アンジオテンシンIIおよびその代謝産物の様々な用量を投与する.
主要な成果:
- アンジオテンシンIIはセロトニンの放出を刺激し,トリプトファンヒドロキシラーゼの活性化によってセロトニンの合成を加速する.
- 高用量では刺激,低用量では阻害という二相的用量依存効果が観察されました.
- 高用量刺激は,アンジオテンシンIIのアンジオテンシンIIIへの変換と関連しており,低用量抑制は他の代謝産物を含む可能性があります.
結論:
- アンジオテンシンIIは,セロトニン系における調節的な役割を果たします.
- セロトニン系は,アニオテンシンIIとその代謝産物によって,微妙な,用量依存の調節が示されています.
- これらの発見は,レニン-アニオテンシン系とセロトニン神経伝達との相互作用を理解するのに役立ちます.
さらに関連する動画
関連する概念動画
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...